Revlimid maintenance use boosts survival, study shows

Celgene's cancer drug Revlimid significantly extended the lives of patients with multiple myeloma who took the drug as a maintenance therapy following a stem cell transplant. But worries about secondary malignancies spooked investors, sending Celgene shares down. Report | Article